A Unique Value Proposition:

We are uniquely positioned to create value for our portfolio companies in the European market by leveraging our proprietary commercialization and distribution platform: CoRRect Medical

Since the early 1990s, CoRRect Medical and its predecessors have successfully commercialized over 20 groundbreaking medical technologies in Europe, establishing new clinical standards of care, including:

  • Transcatheter Aortic Valve Replacement
  • Cerebral Embolic Protection
  • Ultrasound Renal Denervation

CoRRect can help portfolio companies build a strong body of clinical and commercial evidence for their technologies in order to position them for a successful exit - trade sale or initial public offering (IPO). CoRRect’s value proposition comprises:

  • Access to 200+ European hospitals, clinical sites, and Key Opinion Leaders
  • A specialist clinical sales force with experience in introducing novel technologies to market
  • Strategic advice on go-to market strategy (clinical trials, EU regulatory process, reimbursement and pricing)
  • Back-office and logistical support (billing, shipping, warehousing, reporting and accounting)


New technologies commercialized


Clinical accounts


Trusted Key Opinion Leaders


Patients treated